Walleye Capital LLC Takes Position in USANA Health Sciences, Inc. $USNA

Key Points

• Walleye Capital LLC has acquired a new position in USANA Health Sciences, purchasing 12,828 shares valued at approximately $346,000, representing around 0.07% of the company's stock.
• USANA Health Sciences received an upgrade from "hold" to "buy" by Wall Street Zen, with two analysts currently rating the stock as a hold, and an average price target of $36.00.
• The company reported a Q2 EPS of $0.74, exceeding analysts' expectations of $0.54, and had a revenue of $235.85 million for the quarter, surpassing the consensus estimate.

Walleye Capital LLC acquired a new position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 12,828 shares of the company's stock, valued at approximately $346,000. Walleye Capital LLC owned approximately 0.07% of USANA Health Sciences at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Teacher Retirement System of Texas bought a new position in USANA Health Sciences in the 1st quarter worth approximately $888,000. GAMMA Investing LLC grew its holdings in USANA Health Sciences by 49,082.4% in the 1st quarter. GAMMA Investing LLC now owns 8,361 shares of the company's stock worth $225,000 after buying an additional 8,344 shares in the last quarter. US Bancorp DE grew its holdings in USANA Health Sciences by 13.1% in the 1st quarter. US Bancorp DE now owns 4,611 shares of the company's stock worth $124,000 after buying an additional 535 shares in the last quarter. Millennium Management LLC bought a new position in USANA Health Sciences in the 4th quarter worth approximately $633,000. Finally, Exchange Traded Concepts LLC grew its holdings in USANA Health Sciences by 7.1% in the 1st quarter. Exchange Traded Concepts LLC now owns 9,184 shares of the company's stock worth $248,000 after buying an additional 606 shares in the last quarter. 54.25% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider David Mulham Mulham sold 3,515 shares of the stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the sale, the insider owned 9,260 shares in the company, valued at approximately $280,207.60. This represents a 27.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert A. Fuller sold 1,058 shares of the stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $29.10, for a total value of $30,787.80. The disclosure for this sale can be found here. Company insiders own 0.63% of the company's stock.

Analysts Set New Price Targets

Separately, Wall Street Zen raised USANA Health Sciences from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $36.00.

USANA Health Sciences Stock Down 0.5%

NYSE USNA traded down $0.16 on Tuesday, reaching $30.78. 16,626 shares of the stock traded hands, compared to its average volume of 171,759. The firm's fifty day simple moving average is $31.24 and its 200 day simple moving average is $29.56. The company has a market cap of $562.26 million, a price-to-earnings ratio of 17.10, a P/E/G ratio of 1.01 and a beta of 0.64. USANA Health Sciences, Inc. has a 12 month low of $23.10 and a 12 month high of $41.83.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.54 by $0.20. The firm had revenue of $235.85 million during the quarter, compared to analyst estimates of $225.20 million. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. As a group, equities research analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.